4.强化产研协同与数据资产积累：与北京健国医疗的合作，进一步巩固了公司与国家级科研机构的协作 网络。共建长期研究队列所获得的真实世界数据，将成为驱动公司算法迭代、产品优化及创新研发的宝 贵资产。 2.推动行业标准建立与市场规范化：参与国标研究与多中心样本验证，不仅有助于积累高级别循证医学 证据，更能直接参与行业标准的塑造。这将提升公司解决方案的行业认可度与权威性，为产品在全国范 围内的大规模推广奠定坚实基础。 3.拓展普惠性服务网络与社会影响力：项目聚焦于精神卫生福利机构及社区场景，旨在提升基层与特定 机构的认知障碍服务能力。成功实施将显着扩大公司产品与服务的覆盖人群，特别是提升在公共卫生与 社会福利体系中的渗透率，创造显着社会效益的同时，开拓新的市场增长空间。 脑动极光-B(06681)发布公告，公司的间接全资附属公司浙江脑动极光医疗科技有限公司("浙江脑动极 光")已与北京健国医疗科技有限公司("北京健国医疗")正式签署《认知数字疗法项目合作协议》。双方 将于2026年1月1日至2026年12月30日期间，围绕"认知功能评估训练精神卫生应用场景构建与推广应 用"课题开展深度合作，共同推动认知障碍数字疗法的 ...

智通财经APP讯，脑动极光-B(06681)发布公告，公司的间接全资附属公司浙江脑动极光医疗科技有限公 司("浙江脑动极光")已与北京健国医疗科技有限公司("北京健国医疗")正式签署《认知数字疗法项目合 作协议》。双方将于2026年1月1日至2026年12月30日期间，围绕"认知功能评估训练精神卫生应用场景 构建与推广应用"课题开展深度合作，共同推动认知障碍数字疗法的标准化、规模化与可及化。 本次合作是公司继参与国家科技重大专项及获批认知障碍数字疗法北京市重点实验室后，在认知障碍数 字疗法应用落地与生态构建方面的又一重要举措。具体而言，本次合作将： 1.深化精神健康领域技术探索与产品化：通过与国家级研究中心的课题执行方合作，公司将深入精神卫 生这一特定应用场景，探索并验证数字疗法在评估、训练及管理路径上的创新模式。这有助于将前沿人 工智能算法与临床实际需求深度融合，催生更精准、更普适的技术产品，拓展数字疗法在精神健康领域 的应用边界。 4.强化产研协同与数据资产积累：与北京健国医疗的合作，进一步巩固了公司与国家级科研机构的协作 网络。共建长期研究队列所获得的真实世界数据，将成为驱动公司算法迭代、产品优化及创新 ...

格隆汇1月4日丨脑动极光-B(06681.HK)宣布，公司间接全资附属公司浙江脑动极光医疗科技有限公司 ("浙江脑动极光")已与北京健国医疗科技有限公司("北京健国医疗")正式签署《认知数字疗法项目合作协 议》。双方将于2026年1月1日至2026年12月30日期间，围绕「认知功能评估训练精神卫生应用场景构建 与推广应用」课题开展深度合作，共同推动认知障碍数字疗法的标准化、规模化与可及化。 1.国标研究：联合研制认知障碍数字疗法核心技术指标体系、临床验证路径与应用规范，为国家标准立 项提供循证数据与草案文本。 本次合作是公司继参与国家科技重大专项及获批认知障碍数字疗法北京市重点实验室后，在认知障碍数 字疗法应用落地与生态构建方面的又一重要举措。 2.多中心试点：在杭州、南宁、武汉、牡丹江等地精神卫生福利机构及社区同步落地「脑动极光认知功 能评估与训练系统」，预计覆盖80%的目标机构，形成可复制的干预路径。 据悉，北京健国医疗依托北京健国科技集团在高端医疗科技领域的深厚产业基础和项目管理经验，专注 于康复医学技术的临床转化与推广。此次合作，正是双方将前沿数字诊疗算法与成熟产业化体系相结合 的实践，旨在共同推动认 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 自願公告 簽署認知數字療法項目合作協議 本公告為腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願發佈的公告，目的是使廣大投資者瞭解本集團最新業務發展情況。 本公司董事會（「董事會」）欣然宣佈，本公司之間接全資附屬公司浙江腦動極光醫 療科技有限公司（「浙江腦動極光」）已與北京健國醫療科技有限公司（「北京健國醫 療」）正式簽署《認知數字療法項目合作協議》（「本項目」）。雙方將於2026年1月1 日至2026年12月30日期間，圍繞「認知功能評估訓練精神衛生應用場景構建與推 廣應用」課題開展深度合作，共同推動認知障礙數字療法的標準化、規模化與可 及化（「本次合作」）。 背景介紹與本項目總體目標 合作的理由及其裨益 本次合作是 ...

Group 1 - The top three companies with the highest short-selling ratios are Cheung Kong (00001), CLP Holdings (00002), and Hong Kong and China Gas (00003), all reporting a short-selling ratio of 0.00% [1][2] - The top three companies by short-selling amount are also Cheung Kong (00001), CLP Holdings (00002), and Hong Kong and China Gas (00003), with amounts not specified [1][2] - The companies with the highest deviation values are Energy and Energy Global (01142), Hu Shang Ayi (02589), and China Shipbuilding Defense (00317), with deviation values of -0.41%, -0.41%, and -0.66% respectively [1][2] Group 2 - The top ten short-selling ratios include Cheung Kong (00001), CLP Holdings (00002), and Hong Kong and China Gas (00003), all at 0.00%, with significant negative deviation values [2] - The top ten short-selling amounts also feature Cheung Kong (00001), CLP Holdings (00002), and Hong Kong and China Gas (00003), all at 0.00% short-selling ratio and notable negative deviation values [2] - The top ten companies with the highest deviation values include Energy and Energy Global (01142), Hu Shang Ayi (02589), and China Shipbuilding Defense (00317), with deviation values indicating a decline compared to their average short-selling ratios over the past 30 days [2][3]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth driven by favorable policies, technological advancements, and increased investment interest, as evidenced by the recent surge in stock prices of related companies in both Hong Kong and A-share markets [2][6][7]. Policy Developments - The National Medical Products Administration has included implantable brain-computer interface medical devices in the "Priority Approval List for High-end Medical Devices (2025 Edition)" [2]. - A joint initiative by seven ministries, including the Ministry of Industry and Information Technology, has set phased goals for the BCI industry by 2027 and 2030 [3]. - The "14th Five-Year Plan" emphasizes the BCI sector as a key area for fostering new economic growth [4]. - The National Healthcare Security Administration has introduced new pricing guidelines for invasive BCI procedures, facilitating reimbursement pathways [4]. Technological Advancements - Recent breakthroughs in BCI technology include the first domestically developed fully implanted, wireless BCI product by Brain Tiger Technology, which successfully completed its first clinical trial [5]. - The National Medical Products Administration has approved the world's first invasive BCI product for treating addiction-related mental disorders [5]. - Ongoing clinical trials and collaborations among research institutions and medical units are yielding significant progress in the field [5]. Market Insights - The BCI industry is entering a rapid commercialization phase, supported by policy backing, technological breakthroughs, and increased capital influx [5][6]. - The market for BCI is projected to be a nearly $10 billion opportunity globally, with domestic companies making strides in flexible electrodes and real-time Chinese language decoding [7]. - Investment interest in the BCI sector is rising, particularly in rehabilitation applications and non-invasive BCI technologies, as companies strategically position themselves for future growth [6][7].

Group 1 - The stock of Brainstorm Cell Therapeutics Inc. (脑动极光-B) experienced a significant increase, rising over 8% to a peak of 6.82 HKD per share on December 29, with a current price of 6.73 HKD per share at 14:41 [1][4] Group 2 - On December 29, Brainstorm Cell Therapeutics announced a strategic cooperation agreement with LaHespa Health Management Holdings Group (莱贺思宝), focusing on product promotion and market expansion in Singapore [4] - This partnership marks the official launch of the company's market layout and business development in Southeast Asia, leveraging its digital therapy experience and technology accumulated in the Chinese market [4] - The collaboration is expected to enhance the company's brand influence and accelerate product implementation in local medical institutions, thereby shortening the market introduction cycle and expanding into diverse markets in digital health management [4]

Group 1 - The core viewpoint of the article highlights that Brainstorm Cell Therapeutics (06681) has seen a significant stock price increase, rising over 8% during trading and currently up 5.87% to HKD 6.67, with a trading volume of HKD 110 million [1] - The company announced a strategic cooperation agreement with Singapore's Laheyspring Health Management Group to promote product marketing and market expansion in Singapore, aiming to advance the digital health industry [1] - In terms of product promotion, the company will localize and implement its cognitive impairment digital therapy products in Singapore, providing system support and personnel training, while Laheyspring will leverage its offline stores and member resources to recommend the company's products to target users [1] Group 2 - For market expansion collaboration, both parties will integrate resources such as products, channels, brands, and technology to jointly explore the Singapore market, focusing on introducing the company's products into leading private and public hospitals in Singapore to enhance their application and popularity within the local healthcare system [1]

Core Viewpoint - The company, Brainstorm Cell Therapeutics (脑动极光-B), has seen its stock price increase by over 8% during trading, currently up by 5.87% at HKD 6.67, with a trading volume of HKD 110 million, following the announcement of a strategic partnership with Singapore's Lehe Health Management Group [1] Group 1: Strategic Partnership - The company has entered into a strategic cooperation agreement with Lehe Health Management Group to promote and expand its products in the Singapore market [1] - The collaboration will focus on the localization, system implementation, and personnel training support for cognitive impairment digital therapy products in Singapore [1] - Lehe Health Management Group will utilize its offline stores and member resources to target users for the company's products, providing comprehensive services including product introduction, trial guidance, purchase conversion, and after-sales support [1] Group 2: Market Expansion - Both companies will integrate their resources in products, channels, branding, and technology to jointly explore the Singapore market [1] - The partnership aims to facilitate the entry of the company's products into leading private and public hospitals in Singapore, enhancing the application and popularity of its products within the local healthcare system [1]

Core Viewpoint - The company Brainstorm Aurora-B (06681) has entered a strategic cooperation agreement with Singapore's Lehasiba Health Management Group to promote and expand its digital health products in the Singapore market [1] Group 1: Strategic Cooperation - The agreement focuses on product promotion and market expansion collaboration in Singapore [1] - Brainstorm Aurora will localize its cognitive impairment digital therapy products, support system implementation, and provide personnel training [1] - Lehasiba will utilize its offline stores and member resources to recommend the company's products to target users and manage the entire service process, including product introduction, trial guidance, purchase conversion, and after-sales support [1] Group 2: Market Expansion - Both companies will integrate resources such as products, channels, brands, and technology to jointly explore the Singapore market [1] - The collaboration aims to promote the company's products into leading private hospitals and public hospital systems in Singapore, enhancing the application and popularity of the products within the local healthcare system [1]